L. paracasei

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Across the abstracts, Lactobacillus paracasei is most frequently studied in the context of metabolic and immune-mediated conditions, with mechanistic work spanning host–microbe metabolite signaling, intestinal lipid handling, and strain-specific functional outputs. Several lines of research focus on (i) immunomodulation in inflammatory diseases (e.g., rheumatoid arthritis models via gut microbiota remodeling and tryptophan-derived indoles acting through the aryl hydrocarbon receptor, and asthma-related work extending to L. paracasei-derived extracellular vesicles), and (ii) metabolic regulation (e.g., inhibition of enterocyte chylomicron secretion via bacterially produced L-lactate; antidiabetic effects in mice linked to α-glucosidase inhibition and PI3K/Akt-associated gene expression changes). Additional applied studies emphasize production of bioactive bacterial products (e.g., exopolysaccharides and “postbiotic” preparations), survivability/encapsulation strategies, and screening efforts for specific activities (e.g., uric-acid lowering among lactic acid bacteria), reflecting a broader trend toward identifying strain-dependent functional traits.

The strongest evidence in these abstracts supports specific, testable mechanisms in preclinical systems rather than broad clinical efficacy. Notably, controlled mechanistic studies indicate that L. paracasei can alter host physiology through defined metabolites: L-lactate from L. paracasei modulates enterocyte lipid metabolism by promoting malonyl-CoA formation and inhibiting β-oxidation, thereby reducing chylomicron secretion; in arthritis models, enrichment/mono-colonization with L. paracasei (alongside L. casei) is linked to increased microbial tryptophan metabolites (e.g., IA, IPA, IAA) and downstream AhR-associated immune balance (Th17/Treg). For glycemic control, one strain (TD062) shows in vitro α-glucosidase inhibition and dose-dependent improvements in glycemic and metabolic readouts in diabetic mice, with accompanying pathway-level transcriptional changes. Collectively, these findings most strongly support the concept that L. paracasei effects are strain- and product-specific and can be mediated by discrete microbial metabolites or components (including vesicles), with demonstrable impacts in animal models and cell systems.

Key gaps include limited human interventional evidence, incomplete strain comparability, and insufficient standardization of dosing, formulation (live vs heat-killed/postbiotic vs vesicles), and endpoints across indications. Several topics appear early-stage or only partially represented in the provided abstracts (e.g., hyperuricemia screening without detailed outcomes; depression/rosacea/IBD references lacking full results), underscoring the need for well-powered randomized controlled trials that link clinical outcomes to mechanistic biomarkers (metabolites, immune signatures, lipid flux measures) and to genomic/phenotypic characterization of strains. More research is also needed to clarify context dependence (diet, baseline microbiome, co-medications such as immunosuppressants), durability of colonization vs transient functional effects, safety in vulnerable populations, and whether benefits can be reliably reproduced using defined metabolites (e.g., indoles, lactate) or purified bacterial products (EPS, extracellular vesicles) as alternatives to live organisms.

1. What conditions has L. paracasei been studied for?

  • Rheumatoid arthritis (RA) / inflammatory arthritis: In a collagen-induced arthritis (CIA) rat model, L. paracasei was identified as one of two Lactobacillus species enriched/used in mono-colonization linked to reduced arthritis severity in the context of sinomenine treatment.

  • Type 2 diabetes mellitus (T2DM)-related hyperglycemia: In diabetic mice, specific L. paracasei strains (e.g., TD062) were tested for hypoglycemic effects and mechanisms (including α-glucosidase inhibition and PI3K/Akt-related gene expression changes).

  • Intestinal lipid metabolism (relevant to obesity/atherosclerosis/malnutrition): Mechanistic work in enterocytes examined how L. paracasei-derived L-lactate alters chylomicron secretion and lipid handling, with implications for cardiometabolic disease risk.

  • Asthma (especially neutrophilic asthma): L. paracasei-derived extracellular vesicles (LpEV) were studied in relation to asthma phenotypes, including human antibody responses and in vivo/in vitro anti-inflammatory effects.

  • Healthy aging / Alzheimer’s-related amyloid toxicity (preclinical): In C. elegans, L. paracasei HII01 was studied for lifespan extension and protection against β-amyloid toxicity.

  • Food/fermentation-related antioxidant potential: Fermentation with L. paracasei (LP33) in quinoa beverages was studied for effects on phenolic profiles and antioxidant capacity (a functional-food outcome rather than a clinical condition).

  • Other areas mentioned but not fully detailed in the provided abstracts: Hyperuricemia screening of lactic acid bacteria strains; inflammatory bowel disease/colitis models; rosacea; depression; hypercholesterolemia/atherosclerosis; oral health/anti-adhesion; encapsulation to improve survivability; TNF-α inhibition in Caco-2 cells; postbiotics in pediatric infections. (These are referenced only as partial/fragmented abstracts here, so specific L. paracasei outcomes cannot be confirmed from the text provided.)

2. Does it work in treating those conditions? Summarize the evidence.

  • Inflammatory arthritis (CIA rat model; RA-relevant): Evidence is preclinical. In the sinomenine (SIN) study, SIN’s anti-arthritis effect was microbiota-dependent and associated with increased Lactobacillus abundance and higher microbial tryptophan metabolites (IA, IPA, IAA). The abstract states that SIN relieved arthritis symptoms involving enrichment of L. paracasei and L. casei by mono-colonization, and that these species “may be used to reduce the severity of CIA.” This supports potential efficacy in an animal model, but does not establish standalone clinical efficacy in humans.

  • Diabetes/hyperglycemia (diabetic mice): Evidence is preclinical and strain-specific. L. paracasei TD062 showed in vitro α-glucosidase inhibitory activity (31.9%) and, when administered to diabetic mice at varying doses, improved fasting and postprandial blood glucose, glucose tolerance, hepatic glycogen, lipid metabolism, and antioxidant capacity, with some dose dependence. The abstract also reports effects on expression of genes related to glucose metabolism and the PI3K/Akt pathway. This suggests benefit in a mouse model, but does not prove efficacy in humans or for other strains.

  • Lipid metabolism (enterocyte mechanistic study): Evidence is mechanistic rather than a treatment trial. L. paracasei-produced L-lactate inhibited chylomicron secretion and promoted lipid storage via conversion to malonyl-CoA and inhibition of lipid beta-oxidation. The authors suggest therapeutic perspectives for obesity/atherosclerosis/malnutrition, but the abstract does not show clinical outcomes; it shows a plausible pathway by which L. paracasei metabolites can alter lipid handling.

  • Asthma (neutrophilic asthma focus; LpEV): Evidence is mixed translational (human biomarker association + experimental validation). The abstract reports lower proportions of Lactobacillus-genus EVs in a mouse model of neutrophilic asthma and lower serum LpEV-specific IgG4 in patients with neutrophilic asthma vs eosinophilic asthma/healthy controls, with positive correlation to lung function (FEV… text truncated). In vivo/in vitro, LpEV and metabolites showed therapeutic effects by suppressing the JNK pathway and proinflammatory cytokine production in airway epithelium. This supports a potential therapeutic role for extracellular vesicles derived from L. paracasei, but it is not the same as demonstrating that oral L. paracasei supplementation treats asthma in humans.

  • Healthy aging / amyloid toxicity (C. elegans): Evidence is preclinical in worms. L. paracasei HII01 extended lifespan and reduced β-amyloid toxicity in transgenic C. elegans, with involvement of the DAF-16 pathway. This is hypothesis-generating for humans but not directly clinically actionable.

  • Antioxidant/phenolic enhancement in fermented foods: Evidence supports that fermentation with L. paracasei LP33 increased free phenolics/flavonoids and altered bound fractions in quinoa beverages, increasing antioxidant capacity measures. This supports a functional-food effect, not direct treatment of a disease.

Overall, the provided abstracts support potential benefits of certain L. paracasei strains (or their metabolites/vesicles) in multiple preclinical models and mechanistic systems. Human treatment efficacy is not established by these abstracts.

3. What health benefits does it have?

  • Immunomodulation via microbial metabolites (arthritis model): In the CIA rat work, benefits were linked to higher microbial tryptophan metabolites (indole-3-acrylic acid, indole-3-propionic acid, indole-3-acetic acid), activation of aryl hydrocarbon receptor (AhR), and regulation of Th17/Treg balance. L. paracasei was one of the Lactobacillus species implicated in this protective axis.

  • Glycemic control and metabolic effects (strain TD062 in mice): Improvements in fasting/postprandial glucose, glucose tolerance, hepatic glycogen, lipid metabolism, and antioxidant capacity; possible involvement of PI3K/Akt pathway and glucose-metabolism gene expression; plus in vitro α-glucosidase inhibition.

  • Modulation of intestinal lipid handling (mechanistic): L. paracasei-derived L-lactate reduced chylomicron secretion from enterocytes and promoted lipid storage through malonyl-CoA–mediated inhibition of beta-oxidation. Depending on context, reduced chylomicron secretion could be relevant to postprandial lipemia and atherosclerosis risk, though the abstract does not provide clinical endpoints.

  • Airway anti-inflammatory potential (LpEV): L. paracasei extracellular vesicles and metabolites suppressed the JNK pathway and proinflammatory cytokine production in airway epithelium in experimental systems, with human data suggesting lower LpEV immune recognition (IgG4) in neutrophilic asthma.

  • Potential “healthy aging” signals (worm model): Lifespan extension and protection from β-amyloid toxicity in C. elegans, apparently mediated by DAF-16-related pathways.

  • Food-function benefits: Fermentation with L. paracasei LP33 increased free phenolics/flavonoids and antioxidant capacity in quinoa beverages, suggesting potential dietary antioxidant enhancement.

A key limitation across benefits is that many effects are strain-dependent (e.g., TD062, HII01, LP33) and/or rely on specific bacterial products (e.g., L-lactate, extracellular vesicles), so results cannot be assumed for all L. paracasei supplements.

4. Does it have any downsides or side effects?

  • Not reported in the provided abstracts: The abstracts summarized here do not provide systematic adverse event reporting (especially in humans), so side effects cannot be quantified from this evidence set.

  • Potential theoretical/metabolic trade-off (mechanistic lipid study): L. paracasei-derived L-lactate promoted lipid storage in enterocytes while inhibiting chylomicron secretion via reduced beta-oxidation. Depending on the clinical context, promoting lipid storage could be undesirable (e.g., in obesity or fatty liver risk), though the abstract frames the finding as opening therapeutic perspectives and does not demonstrate harm.

  • Product-specific considerations: Some studies focus on extracellular vesicles or fermentation products rather than live bacteria; safety profiles may differ between live probiotics, heat-killed preparations, vesicles, and postbiotics. The provided abstracts do not compare safety across these forms.

Outside these abstracts, probiotics are generally considered safe for many people, but risks can be higher in severely immunocompromised individuals or those with central lines; however, those points are not evidenced within the provided text.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic analyses (e.g., host genetic variants predicting response or adverse effects) for L. paracasei, its extracellular vesicles, or its metabolites.

  • No direct gene–variant guidance: There is no evidence here that specific human genotypes benefit more or are harmed.

  • Mechanistic hints without variant mapping: Some pathways mentioned (AhR signaling in arthritis; PI3K/Akt-related gene expression in diabetic mice; DAF-16 in worms; JNK pathway in airway epithelium) could, in principle, interact with host genetics, but the abstracts do not connect these mechanisms to specific polymorphisms or clinically actionable genetic markers.

References

  1. Sinomenine ameliorates rheumatoid arthritis by modulating tryptophan metabolism and activating aryl hydrocarbon receptor via gut microbiota regulation.
    Zheng-Meng Jiang, Su-Ling Zeng, Tian-Qing Huang, Yang Lin, Fang-Fang Wang, Xing-Jiao Gao, Jing Li, Ping Li, E-Hu Liu (2023) - Science bulletin
  2. Lactobacillus paracasei X11 Ameliorates Hyperuricemia and Modulates Gut Microbiota in Mice.
    Jiayuan Cao, Qiqi Liu, Haining Hao, Yushan Bu, Xiaoying Tian, Ting Wang, Huaxi Yi (2022) - Frontiers in immunology
  3. Fermentation Products of Commensal Bacteria Alter Enterocyte Lipid Metabolism.
    João R Araújo, Asmaa Tazi, Odile Burlen-Defranoux, Sophie Vichier-Guerre, Giulia Nigro, Hélène Licandro, Sylvie Demignot, Philippe J Sansonetti (2020) - Cell host & microbe
  4. In-vitro and in-vivo antibacterial activity of potential probiotic Lactobacillus paracasei against Staphylococcus aureus and Escherichia coli.
    Shadi Shahverdi, Amir Abbas Barzegari, Reza Vaseghi Bakhshayesh, Yousef Nami (2023) - Heliyon
  5. Health-Promoting Properties of
    Ana Agustina Bengoa, Carolina Dardis, Graciela L Garrote, Analía G Abraham (2021) - Foods (Basel, Switzerland)
  6. Postbiotics for Preventing and Treating Common Infectious Diseases in Children: A Systematic Review.
    Jeadran N Malagón-Rojas, Anastasia Mantziari, Seppo Salminen, Hania Szajewska (2020) - Nutrients
  7. Administration of Lactobacillus paracasei ameliorates type 2 diabetes in mice.
    Fangfang Dang, Yujun Jiang, Ruili Pan, Yanhong Zhou, Shuang Wu, Rui Wang, Kejin Zhuang, Wei Zhang, Tiejing Li, Chaoxin Man (2018) - Food & function
  8. Lactobacillus paracasei CCFM1229 and Lactobacillus rhamnosus CCFM1228 Alleviated Depression- and Anxiety-Related Symptoms of Chronic Stress-Induced Depression in Mice by Regulating Xanthine Oxidase Activity in the Brain.
    Mengshu Xu, Peijun Tian, Huiyue Zhu, Renying Zou, Jianxin Zhao, Hao Zhang, Gang Wang, Wei Chen (2022) - Nutrients
  9. Lactobacillus paracasei JY062 Alleviates Glucolipid Metabolism Disorders via the Adipoinsular Axis and Gut Microbiota.
    Yue Su, Jing Ren, Jingwen Zhang, Jiapeng Zheng, Qi Zhang, Yueling Tian, Yu Zhang, Yujun Jiang, Wei Zhang (2024) - Nutrients
  10. Probiotics suppress LL37 generated rosacea-like skin inflammation by modulating the TLR2/MyD88/NF-κB signaling pathway.
    Xinyue Qi, Yiran Xiao, Xinfeng Zhang, Zhenlin Zhu, Hongyan Zhang, Jing Wei, Zhixiang Zhao, Ji Li, Tingtao Chen (2024) - Food & function
  11. Lacticaseibacillusparacasei BNCC345679 revolutionizes DSS-induced colitis and modulates gut microbiota.
    Waqar Ahmad, Ahmad Ud Din, Taj Malook Khan, Mujeeb Ur Rehman, Adil Hassan, Tariq Aziz, Metab Alharbi, Jianbo Wu (2024) - Frontiers in microbiology
  12. Anti-Inflammatory and Gut Microbiota Modulating Effects of Probiotic
    Boonyarut Ladda, Chittapon Jantararussamee, Wisuit Pradidarcheep, Anongnard Kasorn, Udomlak Matsathit, Malai Taweechotipatr (2023) - Nutrients
  13. Supplementation of microencapsulated probiotics modulates gut health and intestinal microbiota.
    Ishwari Gyawali, Guilian Zhou, Guli Xu, Genghui Li, Yujun Wang, Yuxian Zeng, Jincheng Li, Jingjing Zhou, Canjun Zhu, Gang Shu, Qingyan Jiang (2023) - Food science & nutrition
  14. Safety and Effects of
    Jurairat Khongrum, Pratoomporn Yingthongchai, Kongsak Boonyapranai, Wachira Wongtanasarasin, Paitoon Aobchecy, Suriya Tateing, Aree Prachansuwan, Jaruwan Sitdhipol, Kanidta Niwasabutra, Punnathon Thaveethaptaikul, Pongsathon Phapugrangkul, Pennapa Chonpathompikunlert (2023) - Nutrients
  15. The effect of optimized carbon source on the synthesis and composition of exopolysaccharides produced by Lactobacillus paracasei.
    Yu Zhang, Xiaofei Dai, Haonan Jin, Chaoxin Man, Yujun Jiang (2021) - Journal of dairy science
  16. Lactobacillus paracasei-derived extracellular vesicles alleviate neutrophilic asthma by inhibiting the JNK pathway in airway epithelium.
    Soyoon Sim, Hyeon Ju Park, Yoon-Keun Kim, Youngwoo Choi, Hae-Sim Park (2024) - Allergology international : official journal of the Japanese Society of Allergology
  17. Exploring the In Vitro Antibacterial Potential of Specific Probiotic Strains against Oral Pathogens.
    Diletta F Squarzanti, Federica Dell'Atti, Alessandro C Scalia, Ziba Najmi, Andrea Cochis, Patrizia Malfa (2024) - Microorganisms
  18. Lactobacillus paracasei HII01 enhances lifespan and promotes neuroprotection in Caenorhabditis elegans.
    Kishoree K Kumaree, Mani Iyer Prasanth, Bhagavathi Sundaram Sivamaruthi, Periyanaina Kesika, Tewin Tencomnao, Chaiyavat Chaiyasut, Anchalee Prasansuklab (2023) - Scientific reports
  19. Immuno-modulation by heat-killed
    Hazuki Maehata, Satoshi Arai, Noriyuki Iwabuchi, Fumiaki Abe (2021) - International journal of immunopathology and pharmacology
  20. Effect of Lactobacillus (L. acidophilus NCIB1899, L. casei CRL 431, L. paracasei LP33) fermentation on free and bound polyphenolic, antioxidant activities in three Chenopodium quinoa cultivars.
    Jigang Zhang, Xudong Huang, Jianghua Cheng, Chuyan Wang (2023) - Journal of food science


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!